The platform provides facilities to develop of innovative drugs and combination of drugs for stratified therapies, with particular attention to orphan drugs, not patentable drugs and new formulations of administration.
MAIN INFRASTRUCTURES AND METHODOLOGIES AVAILABLE
The platform offers ethical legal and regulatory support for clinical trials of phase I and II, and it offers advice on scientific and regulatory aspects, quality assurance and intellectual propriety related to drug development.
The competence areas of platform are in neurodegenerative disorders, cardiovascular diseases, inflammation, rare diseases and oncology.
The small molecules platform interacts with other product platforms.
Animal care facilities:
In vivo imaging:
Peptides with biological activity:
Two main areas of pharmacology:
HTS (high-throughput screening) platforms:
Collection of chemical compounds:
In Silico models:
Chair: Dr. Pietro Pichierri (ISS)
Co-Chair: Dr. Alfredo Budillon